White Willow Bark Joint Pain: The Trials Measured Hurt, Not Movement

The Oasis Health Journal · Submitted October 6, 2026 · 1:00 PM EDT

By Deke Fontaine · Edited by Hal Weinstock

White willow bark is the tree that gave us aspirin a hundred and twenty-five years ago, and it is back on the supplement shelf as natural joint pain relief.

They asked: does it hurt less?

They did not ask: can the joint bend now?

White Willow Bark Joint Pain Research Measured Feelings, Not Function

A 2023 meta-analysis gathered five studies with six randomized controlled trials covering three hundred and twenty-nine adults with arthritis. Every single one of them used a white willow bark supplement or placebo for anywhere from two to six weeks and then recorded pain scores on visual analog scales, the kind where you put an X on a line between "no pain" and "worst pain imaginable" and a researcher measures it with a ruler.

The results showed significant pain reduction compared to placebo. Stiffness scores improved. Adverse events were about the same as placebo, meaning willow bark was well tolerated and did not wreck anybody's stomach the way NSAIDs sometimes do.

That is all true and it is also where the measurement stopped.

Nobody recorded range of motion. Nobody measured whether participants could climb stairs faster, squat lower, or walk farther at the end of the trial than they could at the beginning. The question was always "how much does it hurt" and never "what can a person do now that they could not do before."

What The Dog Study Measured That The Human Trials Did Not

In 2025, researchers in Italy ran a ninety-day trial on twenty dogs with osteoarthritis, split into two groups: one got a nutraceutical blend containing willow bark extract along with fish oil, turmeric, devil's claw, boswellia and a few other things, and the other group got mavacoxib, a COX-2 inhibitor NSAID.

The researchers measured lameness using a numerical rating scale, pain with two different inventories, AND they measured limb circumference, total pressure index on a force plate, and gait lameness score as a percentage. They took synovial fluid samples. They did radiographs. They tracked whether the dogs were putting weight on the affected leg and whether their stride looked normal.

The willow bark blend performed as well as the NSAID on pain and lameness, and in some measures it did better. More importantly, the trial recorded whether the treatment changed what the dogs could physically do, not just whether they whimpered less.

The human trials for white willow bark joint pain do not do that. They measure the experience of pain, which matters, but they do not measure the mechanical outcome, which is what a person is actually trying to fix when a knee does not want to bend past ninety degrees.

Does White Willow Bark Help With Joint Stiffness You Can Actually Measure?

A 2024 trial tested a different herbal blend containing rosemary, ashwagandha and sesame on adults with chronic back pain for twelve weeks. The researchers used visual analog scales, yes, but they also used the Roland-Morris Disability questionnaire, which asks whether a person can do specific tasks: put on socks, walk, stand for more than half an hour, sleep through the night without pain waking them up.

That is closer. Disability questionnaires at least try to connect the pain score to real activities. But they are still self-reports, not measurements of whether a spine flexes ten degrees farther after twelve weeks or whether someone can lift a case of soda without bracing against the counter.

And that trial was not testing willow bark anyway, so it does not tell us whether joint mobility support from willow bark specifically translates to better movement.

The Compliance Problem Nobody Wants To Talk About

Even if a study DID measure range of motion and stride length and time-to-stand and all the biomechanics we actually care about, a supplement company still could not say "this improves joint mobility" on the label, because that is a structure-function claim that crosses into drug territory the moment it names a condition.

The label can say "supports joint comfort." It cannot say "increases knee flexion by twelve degrees." It definitely cannot name a disease and claim to treat it.

So the industry has no financial incentive to fund a trial that measures whether an elbow bends farther, because even if the trial works, they cannot put the result on the bottle. They CAN say "clinically studied," which only requires that a study happened, not that it measured anything useful.

The asterisk on the label does more work than the molecule.

That is why we get five trials on pain scores and zero trials on goniometer readings.

What We Actually Know About White Willow Bark For Joint Pain Right Now

Willow bark extract contains salicin, which the body converts to salicylic acid, the same active compound in aspirin but at a much lower and slower-release dose. In the five studies that made it into the 2023 meta-analysis, doses ranged from 120 mg to 240 mg of total extract per day, typically standardized to 60 mg to 120 mg of salicin.

Pain scores dropped in patients with arthritis. Stiffness improved on questionnaires. Adverse events were low and mostly mild. If someone is the person whose knee hurts every morning, that matters.

But we do not know if it helps a person climb stairs, pick up a toddler, kneel in the garden, squat to tie shoes, or do any of the things that hurt BECAUSE a joint does not move the way it used to.

We know it probably makes the joint hurt less while sitting still. We do not know what happens when someone moves.

A 2020 review during the early COVID-19 pandemic evaluated herbal medicines for respiratory symptoms and listed willow bark as "promising" based on historical use and safety profile, not based on trials showing it does anything for lung function. That is about the same level of evidence we have for joints: promising, traditional, probably safe, and missing the one measurement that would tell us if it works for the thing people actually want it to work for.

What A White Willow Bark Supplement Trial Would Need To Measure To Be Useful

If I were designing this trial, here is what I would measure: baseline range of motion with a goniometer on the affected joint. Time to stand from a chair without using hands. Walking speed over twenty meters. Pain scores, sure, but also stride length, step symmetry, and whether people can do five squats at the start versus five squats at the end without their knee screaming at them.

Run it for twelve weeks, not two, because cartilage does not remodel in a fortnight and neither does chronic inflammation. Compare willow bark to placebo and also to a low-dose NSAID so we know where it sits in the spectrum of things that actually work.

And then measure all of that again at six months to see if the effect holds or if people just got used to the pain.

That trial does not exist. We have five trials that asked people to rate their pain on a line and then went home.

I am not accusing pain researchers of phoning it in. I am accusing the FUNDING model of phoning it in, because a supplement company will pay for a trial that produces a marketable claim and will not pay for a trial that produces a measurement they cannot put on the label.

The Part Where I Admit This Still Matters Even Without Range-Of-Motion Data

Look, if a joint hurts and a white willow bark supplement makes it hurt less, that is not nothing. Pain is real, pain interferes with life, and anything that turns the volume down on chronic pain without wrecking the gut or the liver is worth knowing about.

The safety profile is good. The evidence for pain reduction is decent. The mechanism makes sense: salicin works, we have known that since before we had aspirin, and the slower release from whole-plant extract means nobody is spiking their blood with salicylates all at once.

But the gap between "it hurts less" and "a person can move better" is not a small gap. It is the difference between a treatment that makes someone feel better while sitting on the couch and a treatment that lets them get off the couch and do something.

And until somebody measures whether white willow bark joint pain treatment closes that gap, we are all just guessing.

This article is education and reporting on published research. It is not medical advice, and nothing here is intended to diagnose, treat, cure or prevent any disease. Talk to your own clinician about your own situation.

Sources

1. A randomized, double-blind, controlled study on the efficacy of an oral dietary supplement containing fish oil, ASU and phytotherapeutic extracts in canine osteoarthritis, Frontiers in veterinary science (2025).
2. Dietary supplementation with plant extracts for amelioration of persistent myofascial discomfort in the cervical and back regions: a randomized double-blind controlled study, Frontiers in nutrition (2024).
3. Willow Bark (Salix spp.) Used for Pain Relief in Arthritis: A Meta-Analysis of Randomized Controlled Trials, Life (Basel, Switzerland) (2023).
4. COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?, Frontiers in pharmacology (2020).
5. Ethnoveterinary medicines used for ruminants in British Columbia, Canada, Journal of ethnobiology and ethnomedicine (2007).
6. Propolis-Based Solution Application in Extraction Socket Healing: A 3D Split-Mouth Clinical Pilot Study, Cureus (2026).